Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  News


Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 


06/21/2013 | 05:03am US/Eastern

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.


PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.


Jane Baj

PTC Therapeutics, Inc.



Sheryl Seapy

Pure Communications


distributed by
React to this article
Latest news
Date Title
01:11a JOHN LAING : ups asset value as profit slumps
01:11a ST JUDE MEDICAL : Abbott denies plan to put $25bn bid together for St Jude Medical
01:11a PETROCHINA : profit slumps as crude oil drops
01:11a ALDERMORE : Profits double at Aldermore as lending grows
01:11a HANSTEEN : raises £40m for deal
01:11a EVRAZ : misses profit goal by $200m
01:11a ALLIED MINDS : doubles research spend as spin-offs take shape
01:11a PUBLIC PARTNERSHIPS : INPP reveals small value increasen
01:10a ESCAP ECONOMIC AND SOCIAL COMMISSION FOR ASIA AN : launches new online e-learning platform to help build resilience to disasters in Asia-Pacific
01:08a ENSERVE : *berenberg cuts spire healthcare price target to 390 (420) pence - 'buy'
Latest news
Hot News 
MOLYCORP : Massive Mojave mine Molycorp to close, taking nearly 500 jobs
ALDERMORE : Profits double at Aldermore as lending grows
REX AMERICAN RESOURCES : announces earnings drop, share repurchase
ODFJELL SE : Second quarter and first half year result 2015
Halcón Resources Announces Debt Exchanges and Discloses Receipt of Continued Listing Standard Notice from NYSE
Most Read News
08/27 IOWA ENERGY CENTER : Energy Department Announces $10 Million in Funding Opportunities
08/27 Photo Release -- Eckrich and Operation Homefront Honor Military Family
08/27 SHAREHOLDER ALERT : Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in AAC Holdings, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit – AAC
08/27 UNITED COMPANY RUSAL PLC : Cancellation of the Corporate Ruble Bonds
08/27 SHAREHOLDER ALERT : Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Plains All American Pipeline, L.P. or Plains GP Holdings, L.P. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit – PAA, PAGP
Most recommended articles
01:08a China jitters, globalization bode ill for Fed's inflation goal
01:07a Silk Road no stairway to heaven for China's machinery makers
01:03a U.S. retailers prod China for lower prices after devaluation
01:00aDJAs China Celebrates WWII Victory, Businesses Cope With Loss
12:57aDJOil Prices Extend Gains as Markets Rebound